Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0403608 (ureter)
 9,655 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The retinoblastoma (RB) gene was the first tumor suppressor gene isolated and its inactivation is associated with the pathogenesis of several types of human cancer. In this study, we investigated the involvement of the RB gene in bladder and renal cell carcinomas by determining the loss of heterozygosity (LOH) at the RB locus and by DNA, RNA, and protein analysis of the RB gene. Whenever possible, the latter included Western blotting and immunohistochemical staining of the RB protein. In bladder carcinoma, 2 of the 8 cell lines we studied had an inactivated RB gene; one cell line lacked RB expression without a gross RB deletion, whereas the other cell line expressed only the underphosphorylated form of the RB protein. None of 16 low-grade noninvasive bladder carcinomas showed an alteration in RB protein by direct Western blot analysis, whereas 2 of 14 high-grade, invasive tumors had no RB protein as measured by both Western blotting and immunohistochemical staining. This suggests that the loss of RB function may be more important in the progression of bladder cancer than in its initiation, although more extensive studies are required. LOH within the RB locus was observed in 5 of 27 informative cases of primary bladder, ureter, or renal pelvis carcinoma. However, none of the 5 cases with LOH at the RB locus had a functional loss of RB protein expression. In renal cell carcinoma, one of the 12 cell lines had a gross homozygous deletion of the RB gene, and 2 of 32 primary tumors were negative for RB protein expression. LOH at the RB locus also was found in only 2 of 30 informative cases, one of which lacked RB expression. These results are the first to demonstrate the involvement of RB inactivation in the development of advanced primary bladder carcinoma and suggest that RB loss could have a role in certain renal cell carcinomas. Our data, however, show no correlation between LOH at the RB locus in bladder cancer and actual inactivation of the RB gene at the protein level. This may suggest that there is a second tumor suppressor or recessive cancer gene on chromosome 13 in bladder cancer and/or that the mechanism of RB inactivation in bladder cancer frequently involves independent mutations of each RB allele.
 ...
PMID:Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. 191 92

Forty patients with carcinoma in situ of the bladder were reviewed. They included 15 patients with primary carcinoma in situ, 8 with secondary carcinoma in situ and 17 with concurrent carcinoma in situ. Twenty-one (66%) of 32 patients with primary or concurrent carcinoma in situ complained of urinary frequency and pain on urination, whereas no patients with secondary carcinoma in situ complained of such symptoms. Nearly all patients with concurrent or secondary carcinoma in situ had gross hematuria, whereas only 7 (47%) of 15 patients with primary carcinoma in situ had gross hematuria. Two patients without any symptoms were diagnosed by incidental positive urinary cytology. Concurrent carcinoma in situ was always associated with multiple papillary tumor. Dominant grade of the papillary tumor was classified as grade 3 in 11 patients and as grade 2 in 6. The simultaneous presence of carcinoma in situ of the urethra was found in 13 (46%) patients and those of the ureter in 17 (74%). Fourteen patients (35%) with carcinoma in situ developed an invasive carcinoma. Of these, 4 (10%) died of cancer. Bacillus calmette-guerin instillation was effective in 13 of 15 patients (87%). These results indicate that carcinoma in situ of the bladder may develop an invasive cancer, may remain in the epithelia, or may be associated with multiple superficial tumor. It should be emphasized that patients with multiple superficial bladder tumor may be associated with carcinoma in situ even if the superficial tumors are of low grade and urine cytology is negative.
 ...
PMID:[The progress pattern of carcinoma in situ of the urinary bladder]. 192 Oct 16

Combination chemotherapy with methotrexate, etoposide, adriamycin and cisplatin (M-EAP regimen) was administered to 4 patients with advanced epithelial cancer of the urinary tract (Methotrexate 30 mg/M2 day 1, 15 and 22; Etoposide 100 mg/M2 day 1, 2, 15 and 22; Adriamycin 30 mg/M2 day 2; Cisplatin 70 mg/M2 day 2, every 4 weeks). In an attempt to improve the anti-cancer effect of the M-VAC regimen, etoposide was substituted for vinblastine. This series comprised 3 males and 1 female ranging in age from 54 to 68 years (mean age: 63), with a performance status of 1 to 2. The site of the primary lesion was bladder in 3, and left ureter in 1. The clinical response was assessed in 3 of the 4 patients: one achieved complete response and two had partial response. Two of the four died of disease 5 months after chemotherapy. Two of them have been alive for 10 and 8 months with no evidence of disease after chemotherapy. Toxicity included moderate or severe myelosuppression in two patients, and mild to moderate anorexia, vomiting, alopecia, and hiccups in all patients. These preliminary results suggest that the M-EAP regimen is effective against advanced epithelial carcinoma of the urinary tract. However, myelosuppression was a dose-limiting factor.
 ...
PMID:[Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer]. 192 67

To determine the frequency and distribution of extrahepatic and extraskeletal metastases in patients with breast carcinoma, the abdominal CT scans of 260 consecutive patients were systematically evaluated. Extrahepatic and extraskeletal metastases were demonstrated in 26 patients (10%). Confirmation of findings was made by biopsy, autopsy, or by demonstration of progression or regression of disease. Twelve patients (4.6%) demonstrated metastases to the stomach, eleven of whom presented with a linitis plastica pattern. Retroperitoneal and/or mesenteric adenopathy was noted in 10 patients (3.8%), of whom three demonstrated associated hydronephrosis and one demonstrated associated biliary obstruction. Ascites was seen in 14 (5.4%) and peritoneal carcinomatosis in 7 (2.6%). Genitourinary involvement included metastases to the kidney (one case), ureter (one), and uterus (one). Direct invasion of the diaphragm by adjacent pleural metastases (two cases) as well as a soft tissue metastasis (one case) was also demonstrated. Metastases to the ovaries, adrenals, or pancreas could not be identified. Although lesions to the liver and skeleton account for the largest group of metastases from breast carcinoma seen in the abdomen, one should be aware of the potential for other locations of metastatic disease.
 ...
PMID:Distribution of metastases in breast carcinoma: CT evaluation of the abdomen. 193 43

A case of quadruple carcinoma involving the ureter, stomach, transverse colon and rectum is described. All tumours have been removed and the patient is healthy without evidence of disease.
 ...
PMID:A case of quadruple carcinoma with special reference to ureteral cancer. 193 27

We report a case of primary undifferentiated small cell carcinoma of the ureter. A 62-year-old man showed gross hematuria. Retrograde pyelography and CT scan revealed a tumor in the left ureter. The light microscopic examination revealed small cell carcinoma and transitional cell carcinoma. To the best of our knowledge, this is the first report of a small cell carcinoma originating in the ureter in Japan.
 ...
PMID:[A case of small cell carcinoma of the ureter]. 196 58

Inverted papilloma of the pelvis and the ureter is a rather uncommon (only 40 cases in the relevant literature) benign epithelial tumor, occasionally harboring foci of malignancy. Since it does not metastasize, a conservative treatment is advisable, but a strict follow up is always required. The Authors report a case of inverted papilloma of the ureter near which an area of transitional carcinoma was discovered.
 ...
PMID:[Inverted papilloma associated with transitional cell carcinoma in the upper urinary tract: report of one case and review of the literature]. 214 19

This study was undertaken to review the long-term results of multivisceral resection of locally advanced colorectal carcinoma. Between 1964 and 1980, 1042 patients underwent exploratory surgery for colorectal cancer. Of these, 58 patients (5.5%) underwent curative multivisceral resection for suspected contiguous invasion by the primary tumor. Follow-up was complete for all patients. The primary tumors were located in the rectum (38 patients), sigmoid (9 patients), left colon (6 patients), and right colon (5 patients). En bloc resection of other viscera included uterus, adnexa, bladder, vagina, small intestine, abdominal wall, liver, stomach, kidney, and ureter. The operative morbidity and mortality rates were 31% and 1.7%, respectively. Resection margins were free of tumor in 54 patients. In the four patients with tumor-positive resection margins, recurrence of disease was evident between 8 and 22 weeks after surgery (mean survival time, 8.2 months). Carcinomatous invasion of the resected contiguous organ was confirmed in 49 patients (84%). The mean survival time for patients without lymph node metastases was 100.7 months, but it was only 16.2 months (p less than 0.01) for patients with lymph node metastases. Actuarial 5-year disease-free survival rate for patients without lymph node metastases was 76% (36 of 47 patients). None of the patients (0 of 11) with lymph node metastases survived for 5 years. Three of 36 of the 5-year survivors experienced recurrence of disease before the seventh postoperative year; no cancer-related deaths occurred between 7 and 25 years. These data suggest that survival in locally advanced colorectal carcinoma is more dependent on lymph node status than on the extent of local invasion. Effective disease control associated with survival in the long term can be achieved by multivisceral resection.
 ...
PMID:Long-term results of surgical resection of locally advanced colorectal carcinoma. 221 91

The correlation between cell killing and the induction of micro-nuclei was studied for three cell lines after treatment with gamma radiation to investigate whether the frequency of micro-nucleated cells can be used to determine the radiation sensitivity of a cell type. R1 rat rhabdomyosarcoma cells showed a higher sensitivity for the induction of proliferative death than RUC rat ureter carcinoma cells and V79 Chinese hamster cells which had a similar radiation sensitivity. The frequencies of micro-nucleated cells were measured at 48 hours after the treatment. It was determined by time-lapse cinematography that almost all the cells in the treated cultures had divided at that time. Our results indicate that for these cell lines the correlation between the effectiveness for cell killing and the induction of micro-nuclei was the same, within the experimental errors.
 ...
PMID:Comparison of radiation sensitivity for three cell lines as measured by the cloning assay and the micro-nucleus test. 226 14

During the last ten years, 16 patients have been treated for urothelial carcinoma of the upper urinary tract, ten carcinomas of the renal pelvis and six carcinomas of the ureter. Mean age at the time of diagnosis was 64.3 years. The most common symptoms were hematuria, flank pain and loss of weight. The diagnosis was established by intravenous pyelography and retrograde ureteropyelography. Ureteral carcinomas were operated with local resection of the ureter, while carcinomas of the renal pelvis were treated with a nephroureterectomia. Most tumours were highly malignant. Four tumours were non-invasive and, in retrospect, could have been treated with a local resection only. Only 35% of patients with urothelial carcinoma in the upper urinary tract are alive five years after diagnosis.
 ...
PMID:[Urothelial carcinoma of the upper urinary tract. 10 years' material from a central hospital]. 230 6


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>